Taliglucerase Alfa
Mechanism :
Taliglucerase alfa is an analogue of glucocerebrosidase; it is produced by recombinant DNA technology using plant (carrot) cell culture.
Indication :
- Treatment of type 1 Gaucher disease.
Contraindications :
Severe hypersensitivity to taliglucerase alfa or any component of the formulation.
Dosing :
IV: 60 units/kg every 2 weeks; dosing is individualized based on disease severity.
Adverse Effect :
Headache, vomiting, hypersensitivity reaction, antibody reaction, arthralgia, limb pain, pharyngitis, flushing, dizziness, fatigue.
Interaction :
No known significant interactions.
Hepatic Dose :
No dose adjustment recommended.